The current PE ratio of VRTX cannot be calculated, as the latest EPS of -$2.08 is negative. Vertex Pharmaceuticals's last PE ratio on record was 26.83 in March 2024.
The mean historical PE ratio of Vertex Pharmaceuticals over the last eight years is 53.28. Analyzing the last eight years, VRTX's PE ratio reached its highest point in the Sep 2017 quarter at 190.05, with a price of $152.04 and an EPS of $0.8. The Dec 2018 quarter saw the lowest point at 20.11, with a price of $165.71 and an EPS of $8.24.
Maximum annual increase: 137.74% in 2019
Maximum annual decrease: -85.78% in 2018
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | N/A | N/A | $402.7 | -$2.08 |
2023 | 28.96 | 30.04% | $406.89 | $14.05 |
2022 | 22.27 | -7.82% | $288.78 | $12.97 |
2021 | 24.16 | 6.71% | $219.6 | $9.09 |
2020 | 22.64 | -52.65% | $236.34 | $10.44 |
2019 | 47.81 | 137.74% | $218.95 | $4.58 |
2018 | 20.11 | -85.78% | $165.71 | $8.24 |
2017 | 141.38 | N/A | $149.86 | $1.06 |
2016 | N/A | N/A | $73.67 | -$0.46 |
2015 | N/A | N/A | $125.83 | -$2.31 |
2014 | N/A | N/A | $118.8 | -$3.14 |
2013 | N/A | N/A | $74.3 | -$1.98 |
2012 | N/A | N/A | $41.9 | -$0.5 |
2011 | 237.21 | N/A | $33.21 | $0.14 |
2010 | N/A | N/A | $35.03 | -$3.77 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Dec 2024 | N/A | N/A | $402.7 | -$2.08 |
Sep 2024 | N/A | N/A | $465.08 | -$1.85 |
Jun 2024 | N/A | N/A | $468.72 | -$1.89 |
Mar 2024 | 26.83 | -7.35% | $418.01 | $15.58 |
Dec 2023 | 28.96 | 12.16% | $406.89 | $14.05 |
Sep 2023 | 25.82 | -3.94% | $347.74 | $13.47 |
Jun 2023 | 26.88 | 8.43% | $351.91 | $13.09 |
Mar 2023 | 24.79 | 11.32% | $315.07 | $12.71 |
Dec 2022 | 22.27 | -1.55% | $288.78 | $12.97 |
Sep 2022 | 22.62 | 0.09% | $289.54 | $12.8 |
Jun 2022 | 22.6 | -17.22% | $281.79 | $12.47 |
Mar 2022 | 27.3 | 13% | $260.97 | $9.56 |
Dec 2021 | 24.16 | 12.16% | $219.6 | $9.09 |
Sep 2021 | 21.54 | -17.94% | $181.39 | $8.42 |
Jun 2021 | 26.25 | 29.95% | $201.63 | $7.68 |
Stock name | PE ratio | Market cap |
---|---|---|
MRK Merck & Co Inc | 12.81 | $218.75B |
JNJ Johnson & Johnson | 26.6 | $374.05B |
ABBV AbbVie Inc | 85.5 | $362.23B |
GILD Gilead Sciences Inc | 294.45 | $139.34B |
BMY Bristol Myers Squibb Co | N/A | $120.95B |
ENTA Enanta Pharmaceuticals Inc | N/A | $113.06M |
VRTX Vertex Pharmaceuticals Inc | N/A | $124.16B |
The current price to earnings ratio of VRTX cannot be determined, as its EPS of -$2.08 is negative.
Over the last 3 years, the average PE ratio for VRTX stock is 25.1.
Over the last 5 years, the average PE ratio for VRTX stock is 25.33.
The highest quarterly PE ratio in the last eight years has been 190.05 and it was in the Sep 2017 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.